Salvage Chemotherapy Followed by Autologous Stem-Cell Transplantation Using Targeted Busulfan for Refractory Diffuse Large B-Cell Lymphoma With Dialysis-Dependent End-Stage Renal Disease

ConclusionChemotherapy followed by ASCT using a conditioning regimen of reduced melphalan and pharmacokinetically targeted busulfan is a promising strategy for treating patients with relapsed or refractory DLBCL who also have end-stage renal disease and are receiving hemodialysis.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionsOur results demonstrate that the incidence of GVHD after daratumumab is low and did not result in increased exacerbation of GVHD in patients with prior history of GVHD.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionT2B2F is associated with a higher incidence of acute GVHD compared to T1B2F. These results suggest that a lower dose-intensity of thiotepa and busulfan in the TBF regimen may yield better results in AML patients in complete remission.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 27 January 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Xuelin Dou, Yazhen Qin, Yueyun Lai, Hongxia Shi, Xiaojun Huang, Qian JiangAbstractIntroductionTo compare the efficacy and safety of generic and branded imatinib in adults with newly diagnosed chronic myeloid leukaemia in the chronic phase (CML-CP), we retrospectively reviewed data from patients CML-CP receiving generic or branded imatinib.Patients and MethodsA propensity score matching (PSM) study was performed. Cox regression model was used to identify factors associated with responses and outcomes.Results442 adults ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 26 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Meghan Salcedo, Nikoletta Lendvai, Donna Mastey, Julia Schlossman, Malin Hultcrantz, Neha Korde, Sham Mailankody, Alexander Lesokhin, Hani Hassoun, Eric Smith, Urvi Shah, Victoria Diab, Kelly Werner, Heather Landau, Oscar Lahoud, Pamela Drullinsky, Gunjan Shah, David Chung, Michael Scordo, Sergio Giralt
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Decrease in regulatory T cell (Tregs) has been linked to GVHD after alloHCT. The use of daratumumab poses a theoretical concern for GVHD flare because of its effects on Tregs and helper and cytotoxic T cells. In this multicenter, retrospective study of relapsed multiple myeloma patients, who received daratumumab after alloHCT, we demonstrate low incidence of GVHD after daratumumab treatment.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
To compare the efficacy and safety of generic and branded imatinib in adults with newly diagnosed chronic myeloid leukaemia in the chronic phase (CML-CP), we retrospectively reviewed data from patients CML-CP receiving generic or branded imatinib.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
This study suggested that a lower dose-intensity of thiotepa and busulfan (5 mg/kg thiotepa and 2 days of iv busulfan at 6.4 mg/kg (T1B2F) in the TBF regimen may yield better outcomes.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Immunomodulatory drugs (IMiDs) are backbone of myeloma therapy in induction and maintenance therapy after transplant for patients (pts) with Multiple Myeloma (MM). The incidence of IMiD-associated rash is up to 27% (Nardone, et al, Clinical Lymphoma Myeloma and Leukemia. 2013) and importantly heralds a favorable prognosis (Kojima, et al. Blood. 2016) suggesting more robust immune stimulation by this class of drugs; however, lack of optimal management strategy of this toxicity can deprive large subset of pts from maintenance therapy after transplant and lead to potential detrimental impact on survivals.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 621 Source Type: research
ConclusionTh17 cells contribute to the stratification of different treatment stages of MM patients. The level of Th17 cells in patients with newly diagnosed MM is associated with the treatment outcome of complete remission.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study adds to the body of evidence in describing incidence and type of cardiac events experienced by an allogeneic and autologous HSCT population at one institution from 2012-2017. Sixty-five patients (9.8%) experienced cardiac events, including atrial arrhythmia (N = 39), acute heart failure (N = 9), acute coronary syndrome (N = 7), new onset hypertension (N = 9), with a few instances of bradycardia, ventricular arrhythmia, pericardial effusion, and pericarditis. Our multivariable regression analysis identified age (older), creatinine (higher) and history of coronary artery disease to significantly correlate with ris...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chemotherapy | Dialysis | Hemodialysis | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Transplants